Cas:58101-60-3 Methyl 3-cyclopentenecarboxylate manufacturer & supplier

Chemical Name:Methyl 3-cyclopentenecarboxylate

CAS.NO:58101-60-3

Synonyms:methyl cyclopent-3-ene-1-carboxylate;MFCD04038661;2-Cyclopentene-1-carboxylic acid, methyl ester;Methyl 2-cyclopentene-1-carboxylate

Molecular Formula:C₇H₁₀O₂

Molecular Weight:126.153

HS Code:2916209090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:149.2±29.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.474

PSA:26.30000

Exact Mass:126.068077

LogP:1.34

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 1993C 3 / PGIII

Packing Group:

Contact us for information like methyl cyclopent-3-ene-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 2-cyclopentene-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Cyclopentene-1-carboxylic acid, methyl ester Use and application,Methyl 2-cyclopentene-1-carboxylate technical grade,usp/ep/jp grade.

Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Methyl 3-cyclopentenecarboxylate manufacturer The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Methyl 3-cyclopentenecarboxylate supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. Methyl 3-cyclopentenecarboxylate vendor Countries and territories that have confirmed cases: Thailand, Japan, Hong Kong, Singapore, Taiwan, Australia, Malaysia, Macau, Russia, France, the United States, South Korea, Germany, the United Arab Emirates, Canada, Britain, Vietnam, Italy, India, the Philippines, Nepal, Cambodia, Sri Lanka, Finland, Sweden and Spain. Methyl 3-cyclopentenecarboxylate factory Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.